CO5590917A2 - Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 - Google Patents
Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1Info
- Publication number
- CO5590917A2 CO5590917A2 CO04065292A CO04065292A CO5590917A2 CO 5590917 A2 CO5590917 A2 CO 5590917A2 CO 04065292 A CO04065292 A CO 04065292A CO 04065292 A CO04065292 A CO 04065292A CO 5590917 A2 CO5590917 A2 CO 5590917A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- optionally substituted
- groups
- 3alkyl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Un compuesto de fórmula ( I ) y sales, profármacos, solvatos y formas cristalinas de los mismos, farmacéuticamente aceptables, en la cual R1 y R2 independientemente representan:un grupo C1-6alquilo;un grupo (amino)C1-4alquilo en el cual amino se sustituye opcionalmente por uno o más grupos C1-3alquilo;un grupo C3-15carbocíclico no aromático, sustituido de manera opcional;un grupo (C3-12 cicloalquil)C1-3 alquilo;un grupo -(CH2)r(fenil)s en el cual r es 0, 1, 2, 3 ó 4, s es 1 cuando r es 0, de lo contrario 1 ó 2 y los grupos fenilo se sustituyen independientemente de manera opcional por uno, dos o tres grupos representados por Z;naftilo;antracenilo;un grupo heterocíclico de 5 a 8 miembros, saturado, que contiene un nitrógeno y, de manera opcional, uno de los siguientes: oxígeno, azufre o un nitrógeno adicional en donde el grupo heterocíclico se sustituye opcionalmente por uno o más grupos C1-3alquilo, hidroxi o bencilo;1-adamantilmetilo;un grupo - (CH2)tHet en el cual t es 0, 1, 2, 3 ó 4, y la cadena alquileno se sustituye opcionalmente por uno o más grupos C1-3alquilo y Het representa un heterociclo aromático sustituido de manera opcional por uno, dos o tres grupos seleccionados de un grupo C1-5alquilo, un grupo C1-5alcoxi o halo;o R1 representa H y R2 es como se define más arriba; o R1 y R2, junto con el átomo de nitrógeno al cual se unen, representan un grupo heterocíclico de 5 a 8 miembros, saturado, que contiene un nitrógeno y, de manera opcional, uno de los siguientes: oxígeno, azufre o un nitrógeno adicional; en donde el grupo heterocíclico se sustituye opcionalmente por uno o más grupos C1-3alquilo, hidroxi o bencilo;X es CO ó SO2;Y está ausente o representa NH sustituido en forma opcional por un grupo C1-3alquilo;R3 y R4 independientemente representan fenilo, tienilo o piridilo cada uno de los cuales se sustituye en forma opcional por uno, dos o tres grupos representados por Z; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590917A2 true CO5590917A2 (es) | 2005-12-30 |
Family
ID=20286429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04065292A CO5590917A2 (es) | 2001-12-19 | 2004-07-09 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7342019B2 (es) |
| EP (1) | EP1458690B1 (es) |
| JP (1) | JP2005517655A (es) |
| KR (1) | KR20040068286A (es) |
| CN (1) | CN1620438A (es) |
| AR (1) | AR038044A1 (es) |
| AT (1) | ATE354570T1 (es) |
| AU (1) | AU2002352425A1 (es) |
| BR (1) | BR0214989A (es) |
| CA (1) | CA2469786A1 (es) |
| CO (1) | CO5590917A2 (es) |
| DE (1) | DE60218340T2 (es) |
| ES (1) | ES2280599T3 (es) |
| HU (1) | HUP0402026A3 (es) |
| IL (1) | IL162377A0 (es) |
| IS (1) | IS7314A (es) |
| MX (1) | MXPA04005990A (es) |
| NO (1) | NO20043022L (es) |
| NZ (1) | NZ533275A (es) |
| PL (1) | PL369731A1 (es) |
| RU (1) | RU2004116916A (es) |
| SE (1) | SE0104330D0 (es) |
| TW (1) | TW200410694A (es) |
| WO (1) | WO2003051851A1 (es) |
| ZA (1) | ZA200404805B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2006527770A (ja) * | 2003-06-18 | 2006-12-07 | アストラゼネカ アクチボラグ | Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体 |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| AR046132A1 (es) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento |
| EP1680116A1 (en) * | 2003-10-24 | 2006-07-19 | Solvay Pharmaceuticals GmbH | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| BRPI0517434A (pt) | 2004-10-25 | 2008-10-07 | Solvay Pharm Gmbh | composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados |
| CA2602787C (en) | 2005-04-06 | 2013-12-24 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| US20100063081A1 (en) | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| CA2664119A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
| EP2114936A1 (en) | 2007-01-04 | 2009-11-11 | Prosidion Limited | Piperidine gpcr agonists |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| JP2010514828A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH458361A (de) | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
| JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
| EP0397859A4 (en) | 1987-11-12 | 1990-12-19 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
| JPH06501926A (ja) | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003051851A1 (en) | 2003-06-26 |
| EP1458690A1 (en) | 2004-09-22 |
| TW200410694A (en) | 2004-07-01 |
| DE60218340D1 (de) | 2007-04-05 |
| NZ533275A (en) | 2006-02-24 |
| ZA200404805B (en) | 2005-08-15 |
| MXPA04005990A (es) | 2004-09-27 |
| IL162377A0 (en) | 2005-11-20 |
| AU2002352425A1 (en) | 2003-06-30 |
| SE0104330D0 (sv) | 2001-12-19 |
| AR038044A1 (es) | 2004-12-22 |
| RU2004116916A (ru) | 2005-11-10 |
| DE60218340T2 (de) | 2007-11-29 |
| BR0214989A (pt) | 2004-12-14 |
| HUP0402026A2 (hu) | 2005-02-28 |
| NO20043022L (no) | 2004-07-15 |
| PL369731A1 (en) | 2005-05-02 |
| ES2280599T3 (es) | 2007-09-16 |
| JP2005517655A (ja) | 2005-06-16 |
| CA2469786A1 (en) | 2003-06-26 |
| IS7314A (is) | 2004-06-16 |
| ATE354570T1 (de) | 2007-03-15 |
| US7342019B2 (en) | 2008-03-11 |
| US20050032808A1 (en) | 2005-02-10 |
| KR20040068286A (ko) | 2004-07-30 |
| EP1458690B1 (en) | 2007-02-21 |
| CN1620438A (zh) | 2005-05-25 |
| HUP0402026A3 (en) | 2005-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5590917A2 (es) | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| AR047683A1 (es) | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos | |
| PE52399A1 (es) | Metodo para usar compuestos neurotroficos de sulfonamida | |
| ATE102920T1 (de) | Serotonin- und norepinephrin-aufnahmeinhibitoren. | |
| TW200507839A (en) | Therapeutic agents | |
| AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen | |
| BG106566A (en) | Aromatic nitrogenous six-membered ring compounds | |
| RS52978B (en) | FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS | |
| AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| RS51394B (en) | SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS | |
| DK0850221T3 (da) | Meta-guanidin-, urinstof-, thiourinstof- eller azacykliske aminobenzoesyrederivater som intergrinantagonister | |
| AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
| EA200400893A1 (ru) | N-арил-2-оксазолидинон-5-карбоксамиды, их производные и их применение в качестве антибактериальных средств | |
| ES2213831T3 (es) | Inhibidores de cisteina-proteasa. | |
| EA200200446A1 (ru) | НОВЫЕ α-АМИНОКИСЛОТНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| HRP20090264T1 (en) | Phenyl-piperazin methanone derivatives | |
| HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
| CO5540307A2 (es) | Derivados de piperidina utiles como moduladores de la activi dad del receptor de quimoquina | |
| CO4970807A1 (es) | Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos | |
| DK1717229T3 (da) | Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| CO5021199A1 (es) | Derivados de 8-fenilxantina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |